Department of Health & Human Services Centers for Medicare & Medicaid Services

Printed: 05/27/2025 Form Approved OMB No. 0938-0391

(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER: 365906	(X2) MULTIPLE CONSTRUCTION A. Building B. Wing	(X3) DATE SURVEY COMPLETED 08/30/2023	
NAME OF PROVIDER OR SUPPLIER Monarch Meadows Nursing and Rehabilitation		STREET ADDRESS, CITY, STATE, ZIP CODE	
habilitation	Seaman, OH 45679		
plan to correct this deficiency, please cont	tact the nursing home or the state survey a	agency.	
prior to initiating or instead of contine medications are only used when the **NOTE- TERMS IN BRACKETS He Based on record review, staff interview appropriate indication. This affected medications during the complaint s Findings include: Closed record review for Resident s diagnoses including dementia, dep admission Minimum Data Set (MDS have severely impaired cognition. Review of the physician's order, da milligrams (mg) of Seroquel (an ani order, dated 01/31/23, revealed Re morning and 50 mg of Seroquel at mood disturbance, and anxiety. The to be administered 25 mg of Seroque behavioral disturbance, psychotic of Interview with the Director of Nursing administered the anti-psychotic me behavioral disturbance, psychotic of Review of the FDA Black Box Warr dementia-related psychosis treated not approved for the treatment of p	nuing psychotropic medication; and PR e medication is necessary and PRN us IAVE BEEN EDITED TO PROTECT C view, and review of the Food and Drug e the anti-psychotic medication Seroqu d one (Resident #41) of three residents urvey. The facility census was 40. #41 revealed the resident was admitter ression, and chronic obstructive pulmo S) assessment, dated 01/17/23, reveal ted 01/12/23, revealed Resident #41 w ti-psychotic medication) twice a day for isident #41 was ordered to be administ night for dementia without behavioral of e physician's order, dated 02/10/23, re uel in the morning and 50 mg of Seroqu disturbance, mood disturbance, and an ing (DON) on 08/29/23 at 2:45 P.M. ver dication Seroquel for diagnoses of anx disturbance, mood disturbance, and an ing for the medication Seroquel revea I with antipsychotic drugs are at an incr atients with dementia-related psychosi	RN orders for psychotropic se is limited. ONFIDENTIALITY** 42728 Administration (FDA) black box el was administered for an s reviewed for unnecessary d to the facility on [DATE] and had mary disorder. Review of the ed Resident #41 was assessed to vas ordered to be administered 50 r anxiety/agitation. The physicians ered 75 mg of Seroquel in the disturbance, psychotic disturbance, vealed Resident #41 was ordered uel at night for dementia without xiety. ified Resident #41 had been .iety/agitation and dementia without xiety. led elderly patients with reased risk for death. Seroquel is s.	
	IDENTIFICATION NUMBER: 365906 R habilitation Man to correct this deficiency, please cont SUMMARY STATEMENT OF DEFIC (Each deficiency must be preceded by Implement gradual dose reductions prior to initiating or instead of contin medications are only used when th **NOTE- TERMS IN BRACKETS H Based on record review, staff interview warning, the facility failed to ensure appropriate indication. This affected medications during the complaint s Findings include: Closed record review for Resident s diagnoses including dementia, dep admission Minimum Data Set (MDS have severely impaired cognition. Review of the physician's order, da milligrams (mg) of Seroquel (an an order, dated 01/31/23, revealed Re morning and 50 mg of Seroquel at mood disturbance, and anxiety. Th to be administered 25 mg of Seroq behavioral disturbance, psychotic of Interview with the Director of Nursii administered the anti-psychotic me behavioral disturbance, psychotic of Review of the FDA Black Box Warn dementia-related psychosis treated not approved for the treatment of p	IDENTIFICATION NUMBER: A. Building 365906 B. Wing R STREET ADDRESS, CITY, STATE, ZI habilitation 299 Commerce Dr Seaman, OH 45679 Ilan to correct this deficiency, please contact the nursing home or the state survey. SUMMARY STATEMENT OF DEFICIENCIES (Each deficiency must be preceded by full regulatory or LSC identifying informati Implement gradual dose reductions(GDR) and non-pharmacological interprior to initiating or instead of continuing psychotropic medication; and PF medications are only used when the medication is necessary and PRN us **NOTE- TERMS IN BRACKETS HAVE BEEN EDITED TO PROTECT C Based on record review, staff interview, and review of the Food and Drug warning, the facility failed to ensure the anti-psychotic medication Seroqu appropriate indication. This affected one (Resident #41) of three residents medications during the complaint survey. The facility census was 40. Findings include: Closed record review for Resident #41 revealed the resident was admittee diagnoses including dementia, depression, and chronic obstructive pulmor admission Minimum Data Set (MDS) assessment, dated 01/17/23, reveal	

Any deficiency statement ending with an asterisk (*) denotes a deficiency which the institution may be excused from correcting providing it is determined that other safeguards provide sufficient protection to the patients. (See instructions.) Except for nursing homes, the findings stated above are disclosable 90 days following the date of survey whether or not a plan of correction is provided. For nursing homes, the above findings and plans of correction are disclosable 14 days following the date these documents are made available to the facility. If deficiencies are cited, an approved plan of correction is requisite to continued program participation.

LABORATORY DIRECTOR'S OR PROVIDER/SUPPLIER REPRESENTATIVE'S SIGNATURE TITLE

Facility ID: 365906